C7 7 2006
510(k) Summary DE
kK 063453% e214 ®
ArthroCare Corporation ji
ArthroCare ENT Plasma Wands {
General Information
Submitter Name/Address: ArthroCare Corporation
680 Vaqueros Avenue
Sunnyvale, CA 94085-2936
Establishment Registration Number: 2951580
Contact Person: Valerie Defiesta-Ng
Director, Regulatory Affairs
Date Prepared: November 21, 2006
Device Description
Trade Name: ArthroCare” ENT Plasma Wands
Generic/Common Name: Electrosurgical Device and Accessories
Classification Name: Electrosurgical Cutting and Coagulation
Device and Accessories (21 CFR
878.4400)
Predicate Devices
ArthroCare” ENT Plasma Wands K033257, cleared 10/30/03
Product Description
The ArthroCare ENT Plasma Wands are bipolar, single usc, hi gh frequency
electrosurgical devices designed for specific indications in otorhinolaryngology (ENT)
surgery.
xi

fae a
K 063534 Tt * 4 ®
Intended Use a
The ArthroCare ENT Plasma Wands are indicated for ablation, resection, and coagulation
of soft tissue and hemostasis of blood vessels in otorhinolaryngology (ENT) surgery
including: .
=  Adenoidectomy
= Cysts
"Head, Neck, Oral, and Sinus Surgery
"  Mastoidectomy
« Myringotomy with Effective Hemorrhage Control
"Nasal Airway Obstruction by Reduction of Hypertrophic
Nasal Turbinates
* Nasopharyngeal/Laryngeal indications including Tracheal
Procedures, Laryngeal Polypectomy, and Laryngeal
Lesion Debulking
= Neck Mass
= Papilloma Keloids
= Submucosal Palatal Shrinkage
= Submucosal Tissue Shrinkage
= Tonsillectomy
= Traditional Uvulopalatoplasty (RAUP)
= Tumors
= Tissue in the Uvula/Soft Palate for the Treatment of
Snoring
Substantial Equivalence
This Special 510(k) proposes a material modification in for the ArthroCare ENT Plasma
Wands, which were previously cleared under K033257 on October 30, 2003. The
indications for use, technology, principle of operation, dimensional specifications,
performance specifications, labeling and sterilization parameters of the Wands remain
the same as in the predicate cleared 510(k).
Summary of Safety and Effectiveness
The modified ArthroCare ENT Plasma Wands, as described in this submission, are
substantially equivalent to the predicate Wands. The proposed material modification is
not a substantial change or modification, and does not significantly affect the safety or
efficacy of the devices.
xii

2 ¢ DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
“enon Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
ArthroCare Corporation BEC 7 1 2006
% Ms. Valerie Defiesta-Ng
Director, Regulatory Affairs
680Vaqueros Avenue
Sunnyvale, California 94085
Re: K063538
Trade/Device Name: ArthroCare® ENT Plasma Wands
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: Class II
Product Code: GEI
Dated: November 21, 2006
Received: November 24, 2006
Dear Ms. Defiesta-Ng:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications for
use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce
prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that
have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic
Act (Act) that do not require approval of a premarket approval application (PMA). You may,
therefore, market the device, subject to the general controls provisions of the Act. The general
controls provisions of the Act include requirements for annual registration, listing of devices, good
manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class IH] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must comply
with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part
807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the
quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product
radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2— Ms. Valerie Defiesta-Ng
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain other
general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

4

tw \ Ln

Mark N. Melkerson

Director

Division of General, Restorative

and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement
Device Name: ArthroCare® ENT Plasma Wands
510(k) Number: KO6353¢
Indications for use:
The ArthroCare ENT Plasma Wands are indicated for ablation, resection, and coagulation
of soft tissue and hemostasis of blood vessels in otorhinolaryngology (ENT) surgery
including:
"  Adenoidectomy
= Cysts
"Head, Neck, Oral, and Sinus Surgery
"  Mastoidectomy
"  Myringotomy with Effective Hemorrhage Control
* Nasal Airway Obstruction by Reduction of Hypertrophic
Nasal Turbinates
“ Nasopharyngeal/Laryngeal indications including Tracheal
Procedures, Laryngeal Polypectomy, and Laryngeal
Lesion Debulking
"Neck Mass
= Papilloma Keloids
* Submucosal Palatal Shrinkage
* Submucosal Tissue Shrinkage
" Tonsillectomy
* Traditional Uvulopalatoplasty (RAUP)
«= Tumors
"  Tissue.in.the-Uvula/Soft Palate forthe Treatment of
Snoring” *
Prescription Use xX OR Over-the-Counter Use
(Per 21 CFR 801.109)
_ (LEASE DO NOT WRITE BELOW THIS LINE - CONINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Ofitce "\ vice Evaluation (ODE)
(Division Sign-Off) ~
Division of General, Restorat? ¢,
and Neurological Devices
| ol OK
510(k) Number JOOS x

